Introduction European valvular heart disease guidelines define women as a ‘special group’. To explore what factors have led ...
Low levels of vitamin D and its principal circulating form 25-hydroxyvitamin D (25-OH-D) have been linked to many types of adverse outcomes beyond bone health, such as cardiovascular disease. How ...
Background Guidelines strongly recommend reperfusion therapy, including thrombolysis and percutaneous coronary intervention, ...
CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.
Patients with different subtypes of metabolic syndrome experience varying prevalence rates of stroke and ischemic heart disease.
Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an ...
Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an ...
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback